Search

Goflikicept

trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-cov

Oteseconazole

[L41635] This drug was approved by the FDA on April 26, 2022.[L41645] … [L41635] CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes.

Lenalidomide

[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that … Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties.

Oxymetholone

Anabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes. … In 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009).

Rosiglitazone

Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. … Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele.

Witch hazel

Trazodone

[T646] It was initially granted FDA approval in 1981.[L3484] … [A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine

Vorapaxar

Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or wi...

Selumetinib

[A193608] Use of selumetinib in this population has shown efficacy in shrinking associated tumours and is linked to other positive clinical outcomes. … [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved.

Valproic acid

[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. … [A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century.